CRISPRa-Mediated Increase of OPA1 Expression in Dominant Optic Atrophy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26136364 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Giada Becchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCL Institute of Ophthalmology, Faculty of Brain Sciences, London EC1V 9EL, UK. Hauptthemen laut MEDLINE: GTP Phosphohydrolases, Optic Atrophy, Autosomal Dominant, CRISPR-Cas Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fight for Sight, Moorfields Eye Charity, Foundation Fighting Blindness USA.
Abstract (Originalsprache)
Dominant Optic Atrophy (DOA) is the most common inherited optic neuropathy and presents as gradual visual loss caused by the loss of retinal ganglion cells (RGCs). Over 60% of DOA cases are caused by pathogenic variants in the OPA1 gene, which encodes a mitochondrial GTPase essential in mitochondrial fusion. Currently, there are no treatments for DOA. Here, we tested the therapeutic potential of an approach to DOA using CRISPR activation (CRISPRa). Homology directed repair was used to introduce a common OPA1 pathogenic variant (c.2708_2711TTAGdel) into HEK293T cells as an in vitro model of DOA. Heterozygous c.2708_2711TTAGdel cells had reduced levels of OPA1 mRNA transcript, OPA1 protein, and mitochondrial network alterations. The effect of inactivated Cas9 fused to an activator (dCas9–VPR) was tested with a range of guide RNAs (gRNA) targeted to the promotor region of OPA1. gRNA3 and dCas9–VPR increased OPA1 expression at the RNA and protein level towards control levels. Importantly, the correct ratio of OPA1 isoform transcripts was maintained by CRISPRa. CRISPRa-treated cells showed an improvement in mitochondrial networks compared to untreated cells, indicating partial rescue of a disease-associated phenotype. Collectively, these data support the potential application of CRISPRa as a therapeutic intervention in DOA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UCL Institute of Ophthalmology, Faculty of Brain Sciences, London EC1V 9EL, UK.
- William Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
- Pharmacology & Toxicology Department, Faculty of Medicine, Kuwait University, Kuwait City P.O. Box 24923, Kuwait.
- John van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK.
- MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0XY, UK.
- Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge CB2 0QQ, UK.
ORCID-Profile: Giada Becchi, J Paul Chapple, Patrick Yu-Wai-Man, Michael E Cheetham
Förderung
- Fight for Sight
- Moorfields Eye Charity
- Foundation Fighting Blindness USA
- Action Medical Research
- The Wellcome Trust
- UK National Institute of Health Research (NIHR)
- Rosetrees Trust
- Isaac Newton Trust (UK)
Zitieren
APA
Becchi, G., Whitehead, M., Harvey, J. P., Sladen, P. E., Dushti, M., Chapple, J. P., Yu-Wai-Man, P., & Cheetham, M. E. (2025). CRISPRa-Mediated Increase of OPA1 Expression in Dominant Optic Atrophy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136364
Vancouver
Becchi G, Whitehead M, Harvey JP, Sladen PE, Dushti M, Chapple JP, et al. CRISPRa-Mediated Increase of OPA1 Expression in Dominant Optic Atrophy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26136364
BibTeX
@article{Becchi2025,
author = {Becchi, Giada and Whitehead, Michael and Harvey, Joshua P and Sladen, Paul E and Dushti, Mohammed and Chapple, J Paul and Yu-Wai-Man, Patrick and Cheetham, Michael E},
title = {CRISPRa-Mediated Increase of OPA1 Expression in Dominant Optic Atrophy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26136364}
}
EUVIMED